[Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
In the present study on healthy volunteers plasma levels of (5-vinyl-2-quinuclidinyl)--(6-methoxy-4-quinolyl)-methanol (quinidine, Chinidinorm) and ECG were studied after administration of a single oral dose of 492 mg quinidine-base as quinidine-bisulfate in form of two slow-release formulations with different galenics. Both formulations show similar retard-characteristics. Serum concentration curve, area under the serum concentration curve, peak serum quinidine levels (1.44 mg/l for both formulations), apparent elimination rate constant (k2 = 0.0882 and 0.0805 h-1, respectively) and elimination half-life show no significant differences. Under the influence of quinidine there is a small but significant increase of the systolic blood pressure during peak serum quinidine levels. The ECG shows increased QT-duration, T-peak and R-peak. There are no significant differences between the two slow-release formulations.
D000328:Adult; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004562:Electrocardiography; D006801:Humans; D008875:Middle Aged; D011802:Quinidine / Q000008:administration & dosage* / Q000378:metabolism; D013997:Time Factors
D003692:Delayed-Action Preparations; D011802:Quinidine
Relative Bioverfügbarkeit sowie Einfluss von Chindin in Form einer Retard-Zubereitung auf Blutdruck und EKG von gesunden Probanden.